Trial Profile
A Single-centre Study of Certican (Everolimus) as Prophylaxis for Graft-versus-Host Disease Following Post-Transplantation Cyclophosphamide After Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms OCTET-Ever
- 16 Mar 2021 Status changed from active, no longer recruiting to completed.
- 26 Nov 2020 Planned End Date changed from 1 Jun 2019 to 1 Dec 2020.
- 26 Nov 2020 Status changed from recruiting to active, no longer recruiting.